Ebola response missions: To go or not to go? Cross-sectional study on the motivation of European public health experts, December 2014.
Ebola response missions: To go or not to go? Cross-sectional study on the motivation of European public health experts, December 2014. Euro Surveill. 2015;20(12) Authors: Rexroth U, Diercke M, Peron E, Winter C, An der Heiden M, Gilsdorf A PMID: 25846488 [PubMed - in process]
Health authorities in eastern Congo have introduced a new Ebola vaccine produced by Johnson&Johnson, aid group MSF said on Thursday, to help combat the world's second-worst outbreak of the virus on record.
[VOA] Geneva -The World Health Organization says that dangers posed by armed groups in two eastern Democratic Republic of Congo provinces are impeding progress in the battle to stop the spread of the deadly Ebola virus. Latest reports put the number of confirmed Ebola cases at 3,287, including 2,193 deaths.
Ebola has become a worldwide concern as the number of cases has increased dramatically and the geographic areas where Ebola is appearing have widened. Our collection provides the latest information to keep you up-to-date.
A second Ebola vaccine is to be offered to thousands of people in the Democratic Republic of Congo.
[VOA] This week the European Commission gave approval to a Ebola vaccine -- an act that the World Health Organization calls landmark moment for global health and a likely game-changer in the battle against this deadly disease.
U.S. drugmaker Merck&Co Inc on Monday received approval from the European Commission to market its Ebola vaccine, less than a month after a European medicines panel backed the first-ever vaccine against the deadly virus.Reuters Health Information
Nature, Published online: 13 November 2019; doi:10.1038/d41586-019-03509-0Larval fish are eating tiny pieces of plastic in the waters off Hawaii, briefcase-sized labs could transform drug development and regulators have approved the first vaccine against Ebola.
A recap of Tuesday’s top stories: Pneumonia number one killer of children; Australia’s wildfires rage on; Ebola vaccine gets green light; new child labour and trafficking study; Malnutrition soars in Latin America and Caribbean; Intellectual Property chief encourages innovation.
U.S. drugmaker Merck &Co Inc on Monday received approval from the European Commission to market its Ebola vaccine.